Search Results - "Ontañón Nasarre, A"

4CPS-080 Optimisation of antiretroviral therapy: results after simplification to bitherapy with dolutegravir/lamivudine or dolutegravir/rilpivirine by Canalejo Fuentes, MJ, Herrero Muñoz, N, Ontañón Nasarre, A, García Gil, M

“…Background and ImportanceSimplification of antiretroviral therapy with dolutegravir/lamivudine (DTG/3TC) or dolutegravir/rilpivirine (DTG/RPV) improves the…”
Get full text

1ISG-010 Pharmacy staff satisfaction and opinion of new website application for outpatient care by Merino, A, Herrero Muñoz, N, Fernández Román, AB, Hernández Muniesa, B, Pou Alonso, A, Ontañón Nasarre, A, Pedreira Bouzas, J, Canalejo Fuentes, MJ, García Gil, M

“…Background and ImportanceUp until March 2022, medical prescription orders and next appointments were printed on paper for pharmaceutical validation and…”
Get full text

4CPS-090 Health outcomes using direct-acting antiviral drugs for the treatment of patients with hepatitis C virus and F0–F1 liver fibrosis stage by Martín López, M, Hernández Muniesa, B, Ontañón Nasarre, A, Pou Alonso, A, Herrero Muñoz, N, García Gil, M

“…BackgroundIn clinical trials, direct-acting antiviral (DAA) drugs stop hepatitis C virus (HCV) proliferation with efficacy rates near 100% in F0–F1…”
Get full text

CP-056 Patient treatment satisfaction after switching to biweekly subcutaneous peginterferon beta 1a from intramuscular interferon beta 1a by Medina, A Liras, Ferrández, J Sánchez-Rubio, Pérez, A Santiago, Sesmero, JM Martínez, Nasarre, A Ontañón, Olias, C Folguera, Benito, Y Aladro

“…BackgroundPeginterferon beta-1a (PEGIFNβ-1a) is administered subcutaneously biweekly, which is an advantage over other treatment schedules used in multiple…”
Get full text

DI-095 Possible severe eosinophilia induced by dimethyl fumarate in relapsing remitting multiple sclerosis by Román, AB Fernández, Nasarre, A Ontañón, Alonso, A Pou, Rosado, A Andrés, López, C Mayo, Muñoz, N Herrero, Gomez, F, Gil, M García

“…BackgroundDimethyl fumarate (DMF) is prescribed for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS). Although mild to…”
Get full text

Adherencia al tratamiento en pacientes con esclerosis múltiple: factores de riesgo by Rodríguez de Antonio, L.A., Fernández de Córdoba-García, R., Herrero-Muñoz, N., Ontañón-Nasarre, A., García-Castañón, I.

Get full text

4CPS-155 Comparative study for evaluation of the pain, ease of use and preference between two adalimumab administration devices: study adap2017 by Muñoz, N Herrero, Rosado, A Andrés, Muniesa, B Hernández, Lázaro, C Bravo, Román, AB Fernández, Alonso, A Pou, Nasarre, A Ontañón, Gutiérrez, MDM García, López, C Mayo, Gil, M García

“…BackgroundAdalimumab is a monoclonal antibody indicated in immunomediate inflammatory diseases for subcutaneous administration by two different devices:…”
Get full text